Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health Catalyst, Inc. on April 2, 2026, covering events reported as of March 31, 2026. The filing addresses executive leadership transitions and the execution of a transition agreement following the accelerated retirement of the Chief Executive Officer.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the compensation terms of the departing CEO under the Transition Agreement:
- Compensation: Average monthly base salary of $10,000 beginning March 1, 2026.
- Equity Forfeiture: Forfeiture of all unvested restricted stock units (RSUs) and performance-based RSUs eligible for vesting after March 2, 2026.
Material Changes
The primary material change is the acceleration of Daniel Burton's retirement from the position of Chief Executive Officer and principal executive officer to February 12, 2026. Subsequently, on March 31, 2026, the Company entered into a Transition Agreement with Mr. Burton. Under this agreement, he will serve as a strategic advisor until December 31, 2026, in exchange for the aforementioned salary and the forfeiture of unvested equity.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or a discussion of general business risks. The primary contingency noted is the execution of the Transition Agreement, which includes a general release of claims against the Company by Mr. Burton. The full text of the agreement is attached as Exhibit 10.1.
Key Facts for Investor Verification
- Confirm the effective date of Daniel Burton's retirement as February 12, 2026.
- Verify the terms of the Transition Agreement, specifically the $10,000 monthly salary and the forfeiture of unvested equity.
- Review the appointment of a new Chief Executive Officer or interim leadership structure, as this filing does not name a successor.
- Examine Exhibit 10.1 for the complete legal terms of the Transition Agreement and release of claims.